Top

Published in:

01-04-2003 | Meeting report

25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10–14 December 2002 Update on clinical research

Authors: Alistair Ring, Julia Head

Published in: Breast Cancer Research | Issue 2/2003

Abstract

The Annual San Antonio Breast Cancer Symposium has become a key forum for the presentation and discussion of both translational scientific aspects as well as clinical aspects of breast cancer care. In this report of the 25th Annual Meeting, an update of the salient clinical data is presented. The findings of the CALGB 9741 trial, an updated analysis of the Arimidex, Tamoxifen, Alone or in Combination study, and other significant paper and poster presentations are discussed. Summaries are also given of the clinical plenary lectures and minisymposia on adjuvant therapy and aromatase inhibitors.

Head JE, Ring A: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10–14 December 2002: Update on preclinical and translational research. Breast Cancer Res. 2003, 5: 109-112. 10.1186/bcr575.CrossRefPubMedPubMedCentral

Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N: A randomized trial comparing CEF with CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. Breast Cancer Res Treat. 2002, 76 (suppl 1): A17-

Citron M, Berry D, Cirrincione C, Carpenter J, Hudis C, Gradishar W, Davidson N, Ingle J, Martino S, Livingstone R, Winer E, Muss H, Norton L: Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB INT C9741). Breast Cancer Res Treat. 2002, 76 (suppl 1): A15-

Aman Buzdar on behalf of ATAC Trialists' Group: The ATAC trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow up of 47 months. Presented at the 25th San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. abstract 13 new version-10–14 December 2002

The ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-39. 10.1016/S0140-6736(02)09088-8.CrossRef

Sainsbury R: Beneficial side-effect profile of anastrozole comapred with tamoxifen confirmed by additional 7 months of exposure data: a safety update from the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat. 2002, 76 (suppl 1): A633-

Gnant M, Hausmaninger H, Samonigg H, Mlineritsch B, Taucher S, Luschin-Ebengreuth G, Jakesz R: Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± Zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast Cancer Res Treat. 2002, 76 (suppl 1): A12-

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed

Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Albain K, Cobleigh M, McCullouh C, Fuchs L, Slamon D: Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in aptients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat. 2002, 76 (suppl 1): A35-

10.

Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, Holmes FA, Fehrenbacher L, Overmoyer BA, Reimann JD, Vassel AV, Langmuir VK: Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat. 2002, 76 (suppl 1): A36-

11.

Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S, Rubi S: Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat. 2002, 76 (suppl 1): A20-

Title: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10–14 December 2002 Update on clinical research
Authors: Alistair Ring
Julia Head
Publication date: 01-04-2003
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 2/2003
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr576

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2003

Waist–hip ratio and breast cancer risk in urbanized Nigerian women

Articles selected from Faculty of 1000 in January 2003

Host microenvironment in breast cancer development: Epithelial–mesenchymal transition in breast cancer development

Is there a role for Notch signalling in human breast cancer?

Breast cancer cell lines: friend or foe?

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer